MX2011011333A - Compositions and methods for treating insulin resistance and diabetes mellitus. - Google Patents

Compositions and methods for treating insulin resistance and diabetes mellitus.

Info

Publication number
MX2011011333A
MX2011011333A MX2011011333A MX2011011333A MX2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A
Authority
MX
Mexico
Prior art keywords
fluids
electrokinetically
altered
membrane
insulin resistance
Prior art date
Application number
MX2011011333A
Other languages
Spanish (es)
Inventor
Anthony B Wood
Gregory J Archambeau
Richard L Watson
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of MX2011011333A publication Critical patent/MX2011011333A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
MX2011011333A 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus. MX2011011333A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2011011333A true MX2011011333A (en) 2011-11-18

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011333A MX2011011333A (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus.

Country Status (9)

Country Link
EP (1) EP2424507A4 (en)
JP (2) JP2012525396A (en)
CN (1) CN102413817B (en)
AU (1) AU2010241736B2 (en)
BR (1) BRPI1013992A2 (en)
CA (1) CA2758738A1 (en)
IL (1) IL215925A0 (en)
MX (1) MX2011011333A (en)
WO (1) WO2010126908A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711558A2 (en) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
RS61601B1 (en) 2010-08-05 2021-04-29 Forsight Vision4 Inc Injector apparatus for drug delivery
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
RS62540B1 (en) 2010-08-05 2021-12-31 Forsight Vision4 Inc Apparatus to treat an eye
EP2603202A4 (en) 2010-08-12 2016-06-01 Revalesio Corp Compositions and methods for treatment of taupathy
AR083878A1 (en) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
MX371198B (en) * 2010-11-15 2020-01-22 Boehringer Ingelheim Int VASOPROTECTIVE and CARDIOPROTECTIVE ANTIDIABETIC THERAPY.
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
KR20140020321A (en) * 2011-04-13 2014-02-18 레발레시오 코퍼레이션 Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
WO2013040247A2 (en) 2011-09-16 2013-03-21 Forsight Vision4, Inc. Fluid exchange apparatus and methods
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
CH706747A2 (en) * 2012-07-17 2014-01-31 Hanspeter Steffen Process for hydration, tightening and care of the skin, for the treatment of dermatoses, sunburn and general wounds with electrolysis water produced with diamond electrodes.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
CN105593363A (en) * 2013-12-27 2016-05-18 水活力株式会社 Nanobubble-containing composition and use thereof
WO2016011191A1 (en) 2014-07-15 2016-01-21 Forsight Vision4, Inc. Ocular implant delivery device and method
SG11201700943TA (en) 2014-08-08 2017-03-30 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CA2967330A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
JP6674748B2 (en) * 2015-05-27 2020-04-01 花王株式会社 GLP-1 secretagogue
CN113069681B (en) 2015-11-20 2022-12-23 弗赛特影像4股份有限公司 Method of manufacturing a therapeutic device for sustained drug delivery
ES2837524T3 (en) 2016-04-05 2021-06-30 Forsight Vision4 Inc Implantable ocular drug delivery devices
CN105878194A (en) * 2016-06-07 2016-08-24 沈阳药科大学 Glibenclamide nanocrystal preparation and preparation method thereof
CN106362166B (en) * 2016-10-27 2019-12-10 武汉大学 Function and application of tumor necrosis factor receptor-related pan-scaffold and signaling protein in treatment of fatty liver and type II diabetes
CN111655206B (en) 2017-11-21 2022-10-14 弗赛特影像4股份有限公司 Fluid exchange device for expandable port delivery system and method of use
CN110006871A (en) * 2019-02-20 2019-07-12 常州大学 One cell model and application based on exogenous histamine detection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (en) * 1990-10-02 1992-04-16 Buchholz Klaus L Use of the reaction product of a gas and a liquid, as well as process and device for producing the same
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
WO2002060458A2 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20060275198A1 (en) * 2005-06-03 2006-12-07 BAGLEY David Method for generating structure ozone
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US7832920B2 (en) * 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (en) * 2006-12-26 2008-07-10 Hydrox Kk Antioxidative functional water
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Also Published As

Publication number Publication date
JP2015229678A (en) 2015-12-21
EP2424507A4 (en) 2012-10-24
IL215925A0 (en) 2011-12-29
CN102413817A (en) 2012-04-11
EP2424507A1 (en) 2012-03-07
CN102413817B (en) 2014-12-17
AU2010241736B2 (en) 2016-01-28
BRPI1013992A2 (en) 2016-08-16
AU2010241736A1 (en) 2011-12-22
WO2010126908A1 (en) 2010-11-04
CA2758738A1 (en) 2010-11-04
JP2012525396A (en) 2012-10-22

Similar Documents

Publication Publication Date Title
MX2011011333A (en) Compositions and methods for treating insulin resistance and diabetes mellitus.
MX337862B (en) Compositions and methods for treating multiple sclerosis.
WO2009134929A3 (en) Compositions and methods for treating digestive disorders
MX2010004554A (en) Compositions and methods for treating inflammation.
MX2013001636A (en) Compositions and methods for treatment of taupathy
BR112014010275A2 (en) diabetes treatment formulations
EA201290964A1 (en) Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
BRPI0910368B8 (en) use of one or more bioenhancers, composition for the use of one or more enhancers chosen from bioenhancers and photoenhancers and eye drops for the use of one or more enhancers chosen from bioenhancers and photoenhancers
BRPI0810874A2 (en) IONIC LIQUID, PROCESS TO PREPARE AN IONIC LIQUID, AND USE OF IONIC LIQUIDS.
UA116665C2 (en) Growth differentiation factor 15 (gdf-15) constructs
ATE548677T1 (en) IONIC LIQUID
CL2012003604A1 (en) Heterocyclic compounds derived from substituted pyridine carboxamide; Preparation process; pharmaceutical composition; pharmaceutical combination; use in the treatment of cell proliferative disorders, parkinson's disease, cancer, among others.
BR112015013809A2 (en) exendin-4 derivatives as glp1 / gip double agonists or glp1 / gip / lucagon trigonals, their use and pharmaceutical composition
EA201270802A1 (en) Dimeric fused proteins of VSTM3 and related compositions and methods
BR112014018575A2 (en) Growth Differentiation Factor 15 Polypeptides (gdf-15)
WO2008027420A3 (en) Implantable devices for producing insulin
TW200712059A (en) Ionic liquids of low viscosity
NI201200134A (en) AGONIST POLYPEPTIDES THAT BIND TO DR5
ATE458824T1 (en) CELL-FREE IN VITRO TRANSCRIPTION AND TRANSLATION OF MEMBRANE PROTEINS INTO BONDED PLANAR LIPID LAYERS
ECSP066777A (en) FUROSEMIDE DERIVATIVES AS MODULATORS OF HM74 AND ITS USE FOR INFLAMMATION TREATMENT
ITMI20080570A1 (en) PROCEDURE FOR THE PREPARATION OF POLYBUTADIENE BRANCHED HIGH CONTENT IN UNIT 1.4-CIS
CR8537A (en) HM74 Oxidecahydronaphthalene Modulators
ATE453650T1 (en) SALTS WITH ALKOXYTRIS(FLUORALKYL)BORATE ANIONS
CL2009000878A1 (en) Sulfonamide derived compounds; pharmaceutical composition; and use in the treatment of diseases such as pain, migraine, diabetes, respiratory tract diseases, inflammatory bowel diseases, obesity, among others.
BR112012018427A2 (en) compound use, and method for increasing the ph of an aqueous suspension

Legal Events

Date Code Title Description
FG Grant or registration